Press release
The blood-brain barrier (BBB) penetrating drugs market is estimated to be worth USD 900 million in 2030, predicts Roots Analysis
Roots Analysis is pleased to announce the publication of its recent study, titled, “Blood-Brain Barrier (BBB) Market (2nd Edition), 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and Therapeutics.”
For additional details, please visit
https://www.rootsanalysis.com/reports/view_document/blood-brain-barrier-drug-delivery/310.html or email sales@rootsanalysis.com
The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of BBB penetration technologies and affiliated drugs, over the next decade. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. In addition to other elements, the study includes:
An overview of the overall landscape of BBB penetration technologies, featuring an in-depth analysis of the technologies based on a number of parameters
A detailed assessment of the current market landscape of BBB penetrant drugs.
Identification of contemporary market trends, depicted using three schematic representations, which include [A] a tree map representation, [B] a bubble analysis and [C] an informative heptagon representation.
An insightful competitiveness analysis of BBB penetration technologies, taking into consideration the supplier power and key technology specific information.
Elaborate profiles of prominent technology developers that are engaged in the development of at least four drugs.
An analysis of the partnerships that have been established in the domain, in the period between 2014 and 2020.
An elaborate discussion on the deal structures of various types of technology licensing agreements inked in this domain.An analysis of the investments made in the domain, in the period between 2014 and 2020 (till March).
An in-depth analysis of the various patents that have been filed / granted related to BBB penetration technologies, till November 2019.
An insightful chessboard analysis highlighting the most preferred / popular drug development strategies / paths adopted by majority of the drug developers (with clinical candidates) in order to progress their lead drug candidates.
An assessment of the most commonly targeted disorders affecting the CNS, shortlisted on the basis of number of BBB penetrant drugs in development.
A list of 240+ drug developers targeting Alzheimer’s disease and Parkinson’s disease that are likely to partner with BBB penetration technology providers.
A case study highlighting the working principle of the most common approaches that are being employed for the development of BBB penetration technologies.
An informative analysis of contemporary Google Trends in the time period between 2015 and 2019 (till December) and insights generated from recent news articles related to the BBB, indicating the increasing popularity of this domain.
A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below) :
Type of Payment Model Adopted
Upfront payments
Milestone payments
Type of Molecule
Small Molecules
Biologics
Target Disease Indication
Brain Metastases in Breast Cancer
Glioblastoma Multiforme
Hunter Syndrome
Hurler Syndrome
Leading Technology Platforms
G®-Technology
J-Brain Cargo® Technology
LRP-1 Technology
Trojan Horse Technology
Leading Drug Developers
2-BBB
Angiochem
ArmaGen
JCR Pharmaceuticals
Key Geographical Regions
North America
Europe
Asia-Pacific
Transcripts of interviews held with the following senior level representatives of stakeholder companies
Ram Bhatt (Chief Executive Officer, Chairman and Founder, Innovative California Biosciences International (ICBI))
Frank S Walsh (Chief Executive Officer and Founder, Ossianix)
Pieter Gaillard (Chief Executive Officer and Co-Founder, 2-BBB)
Rob Hutchison (Chief Executive Officer and Chairman, biOasis Technologies)
Mathias Schmidt (Chief Executive Officer, ArmaGen)
Mark L Peterson (Chief Operating Officer, Cyclenium Pharma)
Xavier Rivero (Chief Operating Officer, Sagetis Biotech)
Carole Desseaux (Head of Clinical Affairs, CarThera)
Jamal Temsamani (Head of Drug Development, Vect-Horus)
Kevin Kit Parker (Professor, Wyss Institute, Harvard University)
Key companies covered in the report
Angiochem
ArmaGen
BioArctic
Cyclenium Pharma
Denali Therapeutics
ICB International
Iproteos
JCR Pharmaceuticals
Lauren Sciences
Medesis Pharma
Ossianix
Vect-Horus
For additional details, please visit
https://www.rootsanalysis.com/reports/view_document/blood-brain-barrier-drug-delivery/310.html or email sales@rootsanalysis.com
You may also be interested in the following titles:
1. Novel Coronavirus (Covid-19): Preventive Vaccines, Therapeutics and Diagnostics in Development
2. DNA-Encoded Libraries: Platforms and Services Market
3. Global Stem Cells Market: Focus on Clinical Therapies, 2020–2030
Contact:
Gaurav Chaudhary
gaurav.chaudhary@rootsanalysis.com
Roots Analysis
A430, 4th Floor,
Bestech Business Towers, Sector 66, Mohali, India
sales@rootsanalysis.com
+1 (415) 800 3415
+44 (122) 391 1091
Web: https://www.rootsanalysis.com/
LinkedIn: https://in.linkedin.com/company/roots-analysis
Twitter: https://twitter.com/RootsAnalysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release The blood-brain barrier (BBB) penetrating drugs market is estimated to be worth USD 900 million in 2030, predicts Roots Analysis here
News-ID: 2221627 • Views: …
More Releases from Roots Analysis
Dental 3D Printing Market to Reach $15.8 Billion by 2035, Growing at 13.5% CAGR …
The global dental 3D printing market, valued at USD 4.1 billion in 2025, will grow to USD 5.0 billion in 2026 and reach USD 15.8 billion by 2035, advancing at a CAGR of 13.5% across the forecast period. This growth reflects accelerating adoption of additive manufacturing across dental laboratories, prosthodontic clinics, and orthodontic practices worldwide, driven by a chronic and worsening global burden of oral disease. For investors, technology developers,…
Deep Learning in Drug Discovery and Diagnostics Market to Reach $34.5 Billion by …
The global deep learning in drug discovery and diagnostics market, valued at USD 6.4 billion in 2025, will grow to USD 8.2 billion in 2026 and reach USD 34.5 billion by 2035, advancing at a compound annual growth rate of 17.3% over the forecast period. This expansion reflects accelerating adoption of neural network-based technologies across pharmaceutical R&D and clinical diagnostics, as more than 200 companies compete to bring AI-native solutions…
3D Cell Culture Market to Reach USD 8.90 Billion by 2035, Growing at 14.6% CAGR …
The global 3D cell culture market, valued at USD 2.16 billion in 2025 and projected to reach USD 2.61 billion in 2026, will grow to USD 8.90 billion by 2035, compounding at 14.6% annually over the forecast period. This growth reflects a fundamental shift in biomedical research methodology, as pharmaceutical companies, academic institutions, and contract research organizations accelerate their adoption of three-dimensional cell models to replace conventional animal testing and…
3D Bioprinting Market to Reach $23.1 Billion by 2035 at 17.7% CAGR | Stratasys, …
The global 3D bioprinting market, valued at USD 4.0 billion in 2024, is on course to reach USD 4.6 billion in 2025 and USD 23.1 billion by 2035, expanding at a compound annual growth rate (CAGR) of 17.7% over the forecast period. This sharp growth trajectory reflects intensifying demand across regenerative medicine, tissue engineering, and pharmaceutical drug development, as clinical researchers and biopharmaceutical companies accelerate adoption of bioprinting platforms capable…
More Releases for BBB
Vietnamese energy experts visiting BBB
On their information trip to companies of the renewable energy sector the expert delegation made a stopover at BBB in Weiden/Bavaria on the 26 July 2013. The delegation consisted of employees of companies of the energy sector and officials from the Vietnamese energy ministry. According to their program, which was tailored by the GIZ - a federal enterprise that supports the German government in achieving its objectives in the field…
BBB strengthened international commitment
BBB Umwelttechnik GmbH (BBB) will be attending the ICCI 2013 in Istanbul and the PWEA 2013 in Serock near Warsaw. The technical consulting firm based in Gelsenkirchen and Weiden (Bavaria), is not entering new terrain there: In Turkey and also in Poland BBB has already been active for years.
In Turkey, BBB has provided technical assessments (due diligence) of wind energy projects with a total nominal output of more than 330…
New from BBB Umwelttechnik GmbH (BBB): Measurement Monitoring System (MMS)
BBB Umwelttechnik GmbH (BBB), one of Germany’s leading providers of wind energy services, is offering a new systems solution for monitoring and safeguarding valuable wind measurement data. The Measurement Monitoring System (MMS) was developed in-house by BBB engineers and has several benefits for the clients. The solution enables web-based, location-independent access to real-time wind measurement statistics while eliminating the risk of data loss. Should measuring systems become damaged by lightning,…
BBB enlarges professional competence
Recently, Ahmed Sidahmed (33) supports BBB Umwelttechnik GmbH at the at the main office of Gelsenkirchen as International Project Manager, Electrical Engineering to develop new business segments. His responsibility is to scrutinize electro-technical concepts and contracts in the scope of technical due diligences as well as theiligences as well as the scheduling of these concepts in the middle- and high-voltage level for onshorelevel for onshore and offshore projects. Previously Sidahmed…
15 years of BBB Umwelttechnik GmbH (BBB)
BBB Umwelttechnik GmbH (BBB), one of German’s leading wind energy service providers with sites in Gelsenkirchen and Weiden, is celebrating its 15th anniversary. Following its establishment in the spring of 1996 by Klaus Bergmann and brothers Gerhard and Joachim Binotsch, the wind experts have overseen a continuous expansion of the company. It now has 24 staff members across two sites and offers high-quality engineering services in the fields of technical…
BBB expands business
Günter Laubinger (46) takes over the lead in the field of Contracting and Procurement. In this position, he is responsible for the examination of project specific contracts in the scope of technical due diligences (TDD). The engineering graduate has a wide experience of operational functions within major companies in the wind industry. Most recently he worked as a sales engineer and sales area manager at GAMESA in Spain, responsible for…
